O-triisopropylsilyl-5-bromopyridin-3-ylmethanol | 599206-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: O-triisopropylsilyl-5-bromopyridin-3-ylmethanol
• 英文别名: 3-Bromo-5-((triisopropylsilyloxy)methyl)pyridine；(5-bromopyridin-3-yl)methoxy-tri(propan-2-yl)silane
• CAS: 599206-09-4
• 化学式: C₁₅H₂₆BrNOSi
• 分子量: 344.367
• InChiKey: BAFCQPRCQFMWMA-UHFFFAOYSA-N

物化性质

• 沸点：
  355.3±27.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.54
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  O-triisopropylsilyl-5-bromopyridin-3-ylmethanol 在 potassium permanganate 、 正丁基锂 、 四丁基氟化铵 、 sodium carbonate 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 19.0h， 生成 5-[4-(5-Carboxypyridine-3-carbonyl)benzoyl]pyridine-3-carboxylic acid
  参考文献：
  名称：

  Synthesis of a new and versatile macrocyclic NADH model

  摘要：

  A new macrocyclic NADH model 1 has been designed and synthesised. The new model consists of the same subunits as previously reported models. However, the present model is designed as such that the pyridine nitrogen of the nicotinamide units are not incorporated in the macrocyclic framework. Thus, properties such as solubility can easily be varied by alkylation with an appropriate agent. The macrocyclic framework was prepared in 7 steps. Methylation of the pyridine nitrogens followed by reduction gave the desired model. This model compound was found to reduce methyl benzoylformate stereoselectively in good yield with 48% enantiomeric excess. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(03)00626-4
• 作为产物：
  描述：

  5-溴烟酸 在 咪唑 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 25.5h， 生成 O-triisopropylsilyl-5-bromopyridin-3-ylmethanol
  参考文献：
  名称：

  Synthesis of a new and versatile macrocyclic NADH model

  摘要：

  A new macrocyclic NADH model 1 has been designed and synthesised. The new model consists of the same subunits as previously reported models. However, the present model is designed as such that the pyridine nitrogen of the nicotinamide units are not incorporated in the macrocyclic framework. Thus, properties such as solubility can easily be varied by alkylation with an appropriate agent. The macrocyclic framework was prepared in 7 steps. Methylation of the pyridine nitrogens followed by reduction gave the desired model. This model compound was found to reduce methyl benzoylformate stereoselectively in good yield with 48% enantiomeric excess. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(03)00626-4

文献信息

• (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
  申请人：CoMentis, Inc.

  公开号：US08299267B2

  公开（公告）日：2012-10-30

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

  本发明提供了新颖的β-分泌酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY
  申请人：Ghosh Arun K.

  公开号：US20100286145A1

  公开（公告）日：2010-11-11

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

  本发明提供了新型的β-分泌酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING
  申请人：Ghosh Arun K.

  公开号：US20100286170A1

  公开（公告）日：2010-11-11

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

  本发明提供了新型β-秘鲁酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• Synthesis of a new and versatile macrocyclic NADH model
  作者：Ulrik Gran

  DOI：10.1016/s0040-4020(03)00626-4

  日期：2003.6

  A new macrocyclic NADH model 1 has been designed and synthesised. The new model consists of the same subunits as previously reported models. However, the present model is designed as such that the pyridine nitrogen of the nicotinamide units are not incorporated in the macrocyclic framework. Thus, properties such as solubility can easily be varied by alkylation with an appropriate agent. The macrocyclic framework was prepared in 7 steps. Methylation of the pyridine nitrogens followed by reduction gave the desired model. This model compound was found to reduce methyl benzoylformate stereoselectively in good yield with 48% enantiomeric excess. (C) 2003 Elsevier Science Ltd. All rights reserved.